Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIVA: Disulfiram plus Vorinostat for HIV Latency Reversal
NCT03198559Phase 2Terminated
- Sponsor
- University of Melbourne
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disulfiram and vorinostat in human immunodeficiency virus infection (HIV), sponsored by University of Melbourne. Primary endpoint: Plasma HIV RNA Relative to Baseline at Day 11. Started Aug 2017; status: terminated.
02
Drugs
disulfiramvorinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03198559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198559.